Investegate |F. Hoffmann-La Roche Ltd Announcements | F. Hoffmann-La Roche Ltd: Roche's Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study

Investegate announcements from F. Hoffmann-La Roche Ltd, Roche’s Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study

Related Keywords

United States ,Switzerland ,Japan ,American ,America ,Roche Tecentriq ,Nathalie Altermatt ,Loren Kalm ,Levi Garraway ,Roche Group Media Relations ,Genentech ,American Association For Cancer Research ,Head Of Global Product Development ,Roche Group ,World Health Organization ,American Association ,Cancer Research ,Annual Meeting ,Chief Medical Officer ,Global Product ,Dow Jones Sustainability Indices ,Chugai Pharmaceutical ,Annual Conference ,Unresectable Hepatocellular ,New England Journal ,Liver Cancer ,Reviews Disease ,Investegate Announcements ,Investegate Company Announcements ,F Hoffmann La Roche Ltd ,Lobenewswire ,Lobenewswire And Globenewswire ,Nw ,